Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
Hu
J C
JC
The Breast Unit, St George's Hospital, Blackshaw Road, London SW17 0QT, UK.
Mokbel
K
K
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000517:prevention & control*; D018572:Disease-Free Survival; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use*; D017211:Treatment Failure; D015854:Up-Regulation
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen